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Background: Diazaborine is the only known inhibitor of eukaryotic ribosome biogenesis, but its target is unknown.
Results: Diazaborine binds the AAA-ATPase Drg1 and inhibits its ATP hydrolysis, thereby blocking release of Rlp24 from
pre-60S particles.
Conclusion: Diazaborine blocks ribosome biogenesis by inhibiting the physiological activity of Drg1.
Significance:Our results highlight the potential of the ribosome biogenesis pathway as target for novel inhibitors.
The drug diazaborine is the only known inhibitor of ribosome
biogenesis and specifically blocks large subunit formation in
eukaryotic cells. However, the target of this drug and the mech-
anism of inhibition were unknown. Here we identify the AAA-
ATPase Drg1 as a target of diazaborine. Inhibitor binding into
the second AAA domain of Drg1 requires ATP loading and
results in inhibition of ATP hydrolysis in this site. As a conse-
quence the physiological activity of Drg1, i.e. the release of
Rlp24 from pre-60S particles, is blocked, and further progres-
sion of cytoplasmic preribosome maturation is prevented. Our
results identify the first target of an inhibitor of ribosome bio-
genesis and provide themechanism of inhibition of a key step in
large ribosomal subunit formation.
Ribosomes translate the genetic information into the amino
acid sequence of proteins and are composed of one large and
one small subunit containing ribosomal RNAs (rRNA) and
ribosomal proteins. In eukaryotic cells, the formation of ribo-
somes involves 200 trans-acting factors (nonribosomal pro-
teins), most of which are essential (for a recent introduction to
ribosome biogenesis see Ref. 1). Ribosome biogenesis starts
with the transcription of precursors of ribosomal RNA (pre-
rRNA) in the nucleolus. Joining of ribosomal and nonribosomal
proteins with pre-rRNA results in formation of precursor par-
ticles for the large and small subunits. A complex maturation
pathway driven by transiently joining nonribosomal proteins
leads to export-competent particles that are transported
through the nuclear pore complex into the cytoplasm where
final maturation steps take place. These include release and
recycling of shuttling maturation and export factors and incor-
poration of late joining ribosomal proteins (for review, see Ref.
2).We andothers demonstrated recently that theAAA2protein
Drg1 is a key factor in cytoplasmic pre-60S maturation in yeast
(3–6). Drg1 is composed of an N domain and the two ATPase
domains D1 and D2 and forms hexamers in the presence of
ATP (7–9). The protein is recruited to cytoplasmic pre-60S
particles by direct interaction with the shuttling protein Rlp24
(3). The C-terminal domain of Rlp24 then stimulates ATP
hydrolysis in bothAAAdomains of Drg1. ATP hydrolysis in D2
is essential and triggers the release of Rlp24 from pre-60S par-
ticles whereas ATP hydrolysis in D1 is required for the subse-
quent dissociation from Rlp24. The release of Rlp24 by Drg1
represents a critical event in pre-60S maturation and is a pre-
requisite for downstream maturation steps like the release of
other shuttling factors and association of late joining cytoplas-
mic proteins (3).
We showed previously that the drug diazaborine blocks ribo-
some biogenesis in yeast (10). Diazaborine is a heterocyclic
boron-containing compoundwith strong antimicrobial activity
(11). In Gram-negative bacteria the drug blocks fatty acid bio-
synthesis by inhibiting the enoyl-ACP reductase FabI (12, 13).
In yeast, fatty acid biosynthesis is not affected by diazaborine
(9). Instead, the drug specifically interfereswith large ribosomal
subunit formation (10). Resistance to diazaborine in yeast is
mediated by certain allelic forms of DRG1 (8). However, the
exact relationship betweenDrg1 and the drug remained elusive,
because the basal ATPase activity of Drg1 was not inhibited by
diazaborine in vitro, and direct binding of radiolabeled inhibi-
tor could not be demonstrated using equilibrium dialysis (9).
We showhere that diazaborine binds toDrg1 and specifically
blocks ATP hydrolysis in the D2 domain, thereby preventing
Rlp24 release from pre-60S particles. Thus, our results identify
the target and describe the mechanism of action of the first
specific inhibitor of the ribosome biogenesis pathway.
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EXPERIMENTAL PROCEDURES
Yeast Strains and Growth Conditions—The yeast and bacte-
rial strains used in the present study are listed in Table 1. All
plasmids used are listed in Table 2. Chromosomal deletions or
gene fusions were generated by homologous recombination
using PCR products to transform the respective yeast strain as
described (14). Strains were grown either in yeast extract pep-
tone dextrose (YPD) complex medium or for plasmid mainte-
nance, in synthetic dextrose complete medium supplemented
with the appropriate amino acids.
Tandem Affinity Purification (TAP)—Preribosomal particles
were purified according to the standard TAP protocol (15, 16)
from 4 liters of yeast culture. Strains were treated for 1 h with
100 g/ml diazaborine 2b18 (11), equivalent to 370 M. The
drugwas a kind gift fromGregorHögenauer, a retired professor
of theUniversity ofGraz. Extractswere prepared in bufferA (20
mM HEPES-NaOH, pH 7.5, 10 mM KCl, 2.5 mM MgCl2, 1 mM
EGTA, 1 mM DTT, 0.5 mM PMSF, and Complete protease
inhibitormixture (Roche Applied Science)) and incubated with
300 l of settled IgG beads (GE Healthcare) for 90 min at 4 °C.
Beads were washed four times with 2 ml of buffer A and once
with 2 ml of buffer B (buffer A plus 100 mM NaCl without the
addition of protease inhibitors). Elution of the preribosomal
particles from the IgG beads was performed by digestion with
the tobacco etch virus protease, which cleaves between the pro-
tein A tag and the calmodulin binding moiety of the TAP tag.
Subsequent purification on calmodulin beadswas performed as
described (5).
Fluorescence Microscopy—Strains were grown in YPD to
early log phase and treated with 370 M diazaborine for 1 h.
Cells were then inspected for GFP/YFP fluorescence with a
Zeiss Axioskop fluorescence microscope using a suitable
band pass filter for GFP or YFP, respectively. For immune
fluorescence microscopy, an Rlp24-TAP-tagged strain was
used. After diazaborine treatment, cells were fixed using
buffered formaldehyde. After washing, cells were sphero-
plasted with zymolyase (VWR) in potassium phosphate
buffer, pH 7.0, containing 1.2 M sorbitol and 30 mM -mercap-
toethanol. Spheroplasts were spotted on polylysine-treated
slides, washed with PBS containing 0.1% Triton X-100, and
incubated with BSA to block nonspecific adsorption. As pri-
mary antibody a polyclonal anti-protein A antibody (Sigma)
and as secondary antibody a goat anti-rabbit-AB conjugated
with rhodamine (Amersham Biosciences) were used. Chroma-
tin was stained with DAPI (Invitrogen).
Expression and Purification of Proteins—Drg1 and mutant
variants thereof were expressed in yeast cells as described pre-
viously (9). Cell disruption was carried out in a bead mill (Mer-
ckenschlager) in the presence of 0.6-mm glass beads for 4 min
with CO2 cooling. Fusion proteins were expressed in Esche-
richia coliBL21 codon plus (Table 1). GST-Rlp24Cwas purified
via the GST tag using GSH-agarose beads (Sigma) as
described in Ref. 3. His6 versions of Rlp24C and the Nup116
fragment (codons 1–172) were purified by Ni2 chelating
chromatography on nickel-nitrilotriacetic acid columns
(Qiagen) as described previously (17). All expression plas-
mids are listed in Table 2.
Protein-Protein Interaction—Interaction assays of Drg1 and
Rlp24C in the absence or presence of 370 M diazaborine were
carried out as described in Ref. 3. The eluates were then ana-
lyzed by SDS-PAGE and Coomassie staining.
ATPase Activity Assay—ATPase activity was determined using
the Malachite Green phosphate assay from BioAssaySystems
through measurement of the formation of free inorganic
phosphate (Pi) as described previously (3). If not otherwise
stated, a concentration of 1 mM ATP was used. All samples
TABLE 1
Yeast and bacterial strains used in this study
Genotype Source
Yeast strains
Arx1-TAP MAT leu2 ura3 his3 trp1
ARX1-TAP::TRP1MX6
(5)
GZYX18 MAT ura3 his3 leu2 trp1 drg1–18
ARX1-TAP::TRP1MX6
(5)
FWY111 MATa ura3 leu2 his3 ade2 trp1
afg2–18
(9)
Arx1-TAP drg1-1 MAT leu2 ura3 his3 trp1 drg1–1
ARX1-TAP::TRP1MX6
This study
W303 MATa ade2 ura3 his3 leu2 trp1 S. D. Kohlwein
HKY51 MATa ade2 ura3 his3 leu2 trp1
drg1-1
This study
Arx1-YFP See W303, ARX1-YFP::HISMX6 (6)
Arx1-YFP drg1-1 See HKY51, ARX1-YFP::HISMX6 This study
Arx1-YFP drg1-18 See FWY111, ARX1-YFP::HISMX6 (6)
Nog1-GFP See W303, NOG1-GFP::HISMX6 (5)
Nog1-GFP drg1-1 See HKY51, NOG1-GFP::HISMX6 This study
Nog1-GFP drg1-18 See FWY111, NOG1-GFP::HISMX6 (6)
Tif6-GFP See W303, TIF6-GFP::HISMX6 (5)
Tif6-GFP drg1-1 See HKY51, TIF6-GFP::HISMX6 This study
Tif6-GFP drg1-18 See FWY111, TIF6-GFP::HISMX6 (6)
Bud20-YFP See W303, BUD20-YFP::HISMX6 (6)
Bud20-YFP drg1-1 See HKY51, BUD20-YFP::HISMX6 This study
Bud20-YFP drg1-18 See FWY111, BUD20-YFP::HISMX6 (6)
Nop7-YFP See W303; NOP7-YFP::HISMX6 (6)
Nop7-YFP drg1-1 See HKY51, NOP7-YFP::HISMX6 This study
Nop7-YFP drg1-18 See FWY111, NOP7-YFP::HISMX6 (6)
Rlp24-TAP MAT ade2 ura3 leu2 trp1
RLP24-TAP::TRP1MX6
(5)
Rlp24-TAP drg1-1 See Rlp24-TAP, drg1–1 This study
BY4743 afg2/
AFG2
MATa/MAT his3/his3 leu2/leu2
met15/MET15 LYS2/lys2 ura3/
ura3 YLR397c::kanMX4/YLR397c
Euroscarf
GZAFG2 MAT , ura3, leu2, his3, lys2, trp1,
drg1::kanMX4 [pRS316-Drg1]
This study
E. coli strain
BL21 Codon Plus
(DE3)-RIPL
B F ompT hsdS (rBmB) dcm
Tetr gal  (DE3) endA Hte [argU
ileY leuWproL Camr]
Stratagene
TABLE 2
Plasmids used in this study
Plasmid Relevant marker Source
pAZ7 GST-DRG1 (9)
pAZ8 GST-drg1-1 (9)
pDRG1-EQ1 GST-drg1E346Q (3)
pDRG1-EQ2 GST-drg1E617Q (3)
pDRG1-KA1 GST-drg1K292A This study
pDRG1-KA2 GST-drg1K563A This study
pRS315 CEN, 2, LEU2 (32)
pRS315-DRG1 DRG1 (3)
pRS315-drg1-1 drg1-1 This study
pRS315-drg1-3 drg1-3 This study
pRS315-drg1-4 drg1-4 This study
pRS315-drg1-11 drg1-11 This study
pGEX6P-1 ori ampR lacIq PreScission
Cleavage site GST tag
GE Healthcare
pGEX-Rlp24C GST-RLP24C (3)
pET32a ori ampR lacIq Trx tag-S tag
HIS6 tag
Novagen
pET32-Rlp24C HIS6-RLP24C (441–599 bp) (3)
pET28 ori ampR lacIq HIS6 tag Novagen
pET28-N172 HIS6-NUP116 (1–516 bp) (3)
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were measured in triplicate of at least two independent
experiments. The enzymatic parameters were calculated
with GraphPad Prism.
In Vitro Release Assay—Pre-60S particles, stalled at an early
cytoplasmic maturation step by incubation of the Arx1-TAP
drg1-ts strain at 37 °C for 1 h, were purified from 12 liters of late
log phase cultures using the TAP protocol described above.
Subsequent release reactions were performed as described pre-
viously (3) in the presence of Drg1 variants, His6Nup116 frag-
ment, and ATP. When indicated, 370 M diazaborine was
added, or ATP was replaced by AMP-PNP. After incubation
for 45 min at room temperature, the supernatants contain-
ing released proteins were collected by centrifugation and
analyzed by SDS-PAGE and Western blotting using poly-
clonal antibodies.
Differential Scanning Fluorometry (DSF)—Differential scan-
ning fluorometry was performed in a Corbett Rotor-Gene 6000
device with a constant fluorescence measurement at each stage
(excitation 470 nm/emission 555 nm) based on the method
described in Ref. 18. Samples contained 1.8 M Drg1 and dif-
ferent concentrations of ATP and/or diazaborine in DSF buffer
(20 mM HEPES-KOH, pH 7.0, 150 KOAc, 5 mM Mg(OAc)2, 1
mM DTT). SYPRO Orange (Sigma) was added to a final dilu-
tion of 1:1000, and the reactionmixtures were incubated on ice
for 30 min. 40-l samples were subjected in duplicate to ther-
mal unfolding using a gradient from 25 to 99 °C. The tempera-
ture was raised 1 °C per stage with a delay of 5 s after each step.
The results were analyzed using the Rotor-Gene 6000 Series
software 1.7.
Generation of a Homology Model of Drg1—The model of
Drg1 was built with the automatic homology modeling module
(19) of the YASARA program (20). Initially, 10 models were
built using the two closest templates in the Protein Data Bank
(1R7R and 3CF3, which are both crystal structures of murine
p97 protein) and five slightly different alignments per template
(21). The modeling procedure involved the SCWRL algorithm
(22) for side chain rotamer prediction and hydrogen bonding
network optimization (23), as well as an energy minimization
with explicit solvent shell (19) to generate the final models.
Surprisingly, the models based on template 3CF3 (24) scored
consistently better, even though 1R7R was solved at higher res-
olution (3.6 versus 4.25 Å). The best model obtained a structure
validationZ-score (24) of2.2 (average of dihedral and packing
Z-scores), which is good considering the low resolution tem-
plate. A ProteinData Bank file of themodel is available from the
authors upon request.
RESULTS
Diazaborine Blocks Cytoplasmic Pre-60S Maturation—We
reported previously that certain drg1 mutants are defective in
the release of shuttling proteins from cytoplasmic pre-60S par-
ticles (3, 5, 6).Most shuttling proteins are released and recycled
into the nucleus soon after nuclear export of pre-60S particles
into the cytoplasm. Therefore, these proteins show low abun-
dance in purifications of late preribosomal particles and a
mainly nuclear steady-state localization. In contrast, inhibition
of shuttling factor release by Drg1 inactivation results in their
increased occurrence in preparations of late pre-60S particles
and a mislocalization into the cytoplasm (3, 5, 6) (Fig. 1B). Fur-
thermore, the failure to release these proteins prevents the
binding of later joining factors to these pre-60S particles (3, 5).
The resistant phenotype of certain drg1 alleles prompted us
to investigate whether diazaborine triggers phenotypes similar
to those caused by functional inactivation of Drg1. To investi-
gate whether diazaborine also affects shuttling factor release,
we purified late pre-60S particles by TAP using Arx1 as bait
protein. As shown in Fig. 1A, drug treatment of the wild-type
strain resulted in increased levels of the shuttling proteins
Rlp24 and Nog1 and of the export factors Mex67 and Mtr2 in
these pre-60S purifications. As expected, due to its near stoichi-
ometric presence on Arx1 particles, the levels of Nmd3 showed
only a minor increase relative to the bait protein. Concomi-
tantly, decreased levels of the late joining cytoplasmic proteins
Sqt1 and Rpl10, and to a lesser extent Rei1, were detected in
pre-60S preparations upon diazaborine treatment. In contrast,
no alterations in the composition of late pre-60S particles were
observed upon diazaborine treatment of the resistant drg1-1
mutant, which carries a V725E exchange in the polypeptide
chain. These results suggest a block of shuttling protein release
from the pre-60S particles in the presence of diazaborine.
We next asked whether this blockage takes place in the cyto-
plasm as is the case in drg1-ts mutants (5, 6). For this purpose
GFP or YFP fusions of representative shuttling factors were
inspected by fluorescence microscopy after diazaborine
treatment. The shuttling proteins Arx1, Nog1, Bud20, and
Rlp24, which showed a predominantly nuclear localization in
untreated cells, accumulated in the cytoplasm after treatment
with diazaborine (Fig. 1, B and C). In contrast, no cytoplasmic
mislocalization was observed in the resistant drg1-1 strain or
after diazaborine treatment of strains expressing a YFP fusion
of the strictly nuclear pre-60S maturation factor Nop7. The
phenotype of diazaborine-treated cells strongly resembled that
observed in a drg1-ts mutant shifted to the restrictive temper-
ature (Fig. 1B and Ref. 6).
Together, these results demonstrate that the drug causes a
failure to release shuttling factors frompre-60S particles, which
leads to their accumulation in the cytoplasm in pre-60S bound
form. Notably, as Drg1 was still associated with pre-60S parti-
cles after treatmentwith diazaborine, the drug does not prevent
association of the AAA-ATPase with pre-60S particles in vivo.
Diazaborine Inhibits the Release of Rlp24 from Pre-60S
Particles—Targeting of Drg1 to preribosomal particles as well
as activation of ATP hydrolysis are mediated by the C-terminal
domain of the shuttling factor Rlp24 (3). To investigatewhether
diazaborine affects binding of Drg1 to Rlp24C, we analyzed
their interaction using GST pulldown assays. As shown in Fig.
2A, diazaborine had no effect on the in vitro interaction
betweenDrg1 andRlp24. This is consistentwith the presence of
Drg1 on pre-60S particles from the diazaborine-treated strain
(Fig. 1A).
Because the physiological function ofDrg1 is to release Rlp24
from pre-60S particles, we investigated whether diazaborine
interfereswith this activity using our recently developed in vitro
release assay (3) (Fig. 2B). Briefly, pre-60S particles purified
from a drg1-ts mutant were bound to calmodulin beads and
incubated with ATP and Drg1 in the absence or presence of
Diazaborine Inhibits Drg1
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diazaborine. As our previouswork showed that the nucleoporin
Nup116 is required for the in vitro release of Rlp24 from pre-
60S particles by Drg1 (3) it was also added to the reaction mix-
ture. The amounts of released Rlp24 in the supernatants were
then analyzed by Western blotting. As shown in Fig. 2C, addi-
tion of diazaborine prevented the release of Rlp24 almost com-
pletely (95.0  3.0% inhibition compared with the untreated
control). A similar result was obtained with the nonhydrolyz-
able nucleotide analog AMP-PNP (96.7  1.9% inhibition),
which could be an indication that diazaborine interferes with
ATP hydrolysis of Drg1. To compare the effects of diazaborine
treatment with those caused by inactivation of ATP hydrolysis
Diazaborine Inhibits Drg1
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in the two individual AAA domains, we investigated mutant
variants defective for ATP hydrolysis in the first (Drg1EQ1) or
the second (Drg1EQ2) AAA domain. As shown in Fig. 2D,
Drg1EQ1 was still able to release Rlp24 from purified pre-60S
particles, although to a lesser extent than the wild-type protein
(inhibition of 57.2 10.8%). In contrast, a much stronger inhi-
bition of release was observed whenDrg1EQ2was used (89.0
4.5%). Thus, diazaborine blocksRlp24 release to a similar extent
as inactivation of ATP hydrolysis in the D2 domain of Drg1.
These results are consistent with in vivo data showing that only
ATP hydrolysis in D2 is essential for growth and for the release
of Rlp24 (3).
Binding of Diazaborine to Drg1 Requires Loading of ATP in
D2—The inhibition of the physiological activity of Drg1 by
diazaborine suggests direct interaction of the drug with Drg1.
We therefore measured binding of diazaborine to Drg1 by DSF
(18). This method makes use of the stain SYPRO Orange,
which emits fluorescence only when bound to hydrophobic
regions of proteins that become exposed upon denaturation.
This property enables the recording of melting curves of pro-
teins. The melting temperature can then be deduced from the
first derivative of this curve. Binding of low molecular weight
compounds to proteins frequently results in an increase of their
melting temperature (25). Therefore, plotting the increase in
melting temperature against the compound concentration
allows estimation of quantitative binding parameters.
When diazaborine was added in the absence of ATP, no
alteration of themelting curvewas detected (Fig. 3A). However,
when 5 mM ATP and 740 M diazaborine were simultaneously
present in the sample, a shift of the melting curve to higher
temperatures was observed compared with the sample with
ATP alone (Fig. 3B). We conclude that diazaborine binds
directly to Drg1 and that this interaction requires ATP. The
order of drug and nucleotide addition did not influence the
melting temperature. In addition, increasing ATP concentra-
tions did not inhibit binding of the drug toDrg1, suggesting that
diazaborine does not compete with the nucleotide for binding
to Drg1. We next asked whether ATP binding to the D1 or D2
domain is required to allow interaction with the inhibitor. For
this purpose, we made use of the Drg1KA1 and Drg1KA2 vari-
ants, which are unable to bindATP in the first and secondAAA
domain, respectively. In the presence of ATP, the Drg1KA1
variant showed an additional peak in the melting curve when
diazaborine was present in the sample (Fig. 3C). Thus, nucleo-
tide binding to the D1 domain is not required for diazaborine
binding. In contrast, the melting curve of the Drg1KA2 variant
was not influenced by diazaborine, demonstrating that ATP
binding into the D2 domain of Drg1 is a prerequisite for inter-
action with the inhibitor (Fig. 3D).
To obtain quantitative binding parameters, we recorded
melting curves of Drg1 in the presence of 5 mM ATP and
FIGURE 1. Diazaborine blocks maturation of late pre-60S particles. A, diazaborine treatment leads to the enrichment of shuttling and export factors in
purifications of late pre-60S particles. The DRG1wild-type strain (DRG1 (WT)) and the diazaborine resistant drg1-1mutant (drg1-1 (res)) were treated with 370
M diazaborine for 1 h. Afterward pre-60S particles were isolated with Arx1-TAP as bait protein and analyzed by Western blotting with antibodies directed
against shuttling proteins, export factors, and late joining cytoplasmic factors. B, diazaborine (Dia) triggers the cytoplasmic accumulation of shuttling factors.
Yeast strains expressing chromosomal fusions of shuttling pre-60Smaturation factors Arx1, Nog1, or Bud20with YFP or GFP in theDRG1wild-type (DRG1 (WT))
and thediazaborine resistantdrg1-1mutant (drg1-1 (res))were treatedwithdiazaborine.After 1h, sampleswere inspectedby fluorescencemicroscopy.A strain
expressing a chromosomal fusion of the strictly nuclear pre-60Smaturation factor Nop7 with YFP was used as a control. As a control for cytoplasmic accumu-
lation, the localization of the respective fluorescent proteinswas also inspected in the drg1-tsbackground.DIC, differential interference contrast picture.C, the
shuttling factor Rlp24 accumulates in the cytoplasm after treatment with diazaborine. Immune fluorescence with TAP-tagged Rlp24 is shown. The DRG1
wild-type strain (DRG1 (WT)) or the diazaborine-resistant drg1-1mutant (drg1-1 (res)) expressing Rlp24-TAP fusion proteins were treated with diazaborine for
1 h. Thereafter cells were fixed, and Rlp24-TAP was detected by immunofluorescence. DAPI, DAPI staining of the DNA in the nucleus. Phase, phase contrast
pictures to monitor morphological integrity of the cells.White scale bars in B and C, 5 m.
FIGURE 2.Diazaborine blocks in vitro release of Rlp24. A, diazaborine (Dia)
does not prevent the interaction between Drg1 (WT) and Rlp24. GST-Rlp24C
was immobilized on glutathione-agarose and incubatedwith Drg1 and 1mM
ATP in the presence or absence of 370 M diazaborine. After washing and
elution, eluates were analyzed by SDS-PAGE and Coomassie staining. Input,
purifiedDrg1used in theassay; Std, protein standard.GST servedas control.B,
experimental schema shows in vitro release assay ofC andD. Pre-60Sparticles
isolated from a drg1-tsmutant after incubation at the restrictive temperature
using Arx1-TAP as bait protein are immobilized on Sepharose beads. After
incubationwith Drg1 (WT) and ATP, released proteins (i.e. Rlp24) are found in
the supernatant. Nup116,whichwaspresent in all samples,was omitted from
the schema for simplicity reasons. C, diazaborine blocks Rlp24 release. The
nonhydrolyzable ATP analog AMP-PNP or ATP and 370 M diazaborine were
added to the release assay described in B. The supernatantswere analyzedby
SDS-PAGE and Western blotting with antibodies directed against Drg1 and
Rlp24.Mex67andArx1-TAP,whicharenot releasedbyDrg1,were analyzedas
negative controls. D, ATP hydrolysis in the D2 domain of Drg1 is essential for
the in vitro release of Rlp24. The release assay was performed as in C, using
either wild-type Drg1, wild-type Drg1 and diazaborine, or the D1 or D2 ATP
hydrolysis-defective Drg1 variants Drg1EQ1 andDrg1EQ2, all in the presence
of ATP. Whereas Drg1EQ1 showed only slightly reduced release activity,
Drg1EQ2 was almost completely unable to release Rlp24, resembling diaza-
borine-treated wild-type Drg1.
Diazaborine Inhibits Drg1
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increasing diazaborine concentrations. As shown in Fig. 3E (left
panel), a concentration-dependent shift of themelting temper-
ature was observed. Plotting the increase in melting tempera-
ture (relative to the sample containing ATP alone) against the
drug concentration resulted in a hyperbolic drug binding curve
with a KD of 122.3 4.1M diazaborine (mean of three biolog-
ical replicates, right panel). In contrast to the wild-type, the
protein from the diazaborine-resistant Drg1-1 variant did not
show a change in melting temperature even at high drug con-
centrations (Fig. 3F). We conclude that the resistance of the
Drg1-1 protein to diazaborine arises from the failure of the
inhibitor to bind to this variant.
Resistance Is Caused by Amino Acid Exchanges in the Nucle-
otide Binding Pocket of D2—The drg1-1 allele was originally
identified together with several other alleles in a random
mutagenesis screen for diazaborine-resistant mutants (8) (Fig.
4A). However, the mechanism of how these alleles mediate
resistance was unknown. As indicated in Fig. 4B, all exchanges
identified in themutants are located in the secondAAAdomain
of Drg1. To better understand the mechanism of resistance, we
FIGURE 3. Binding of diazaborine requires ATP loading into the D2 domain of Drg1. Binding of diazaborine (Dia) to Drg1 was investigated by DSF. 1.8M
Drg1 (WT) or mutant variants thereof were incubated with different diazaborine concentrations in the absence or presence of ATP, and melting curves were
recorded in the presence of SYPRO Orange in a Rotor-Gene 6000. A and B, binding of diazaborine to Drg1 requires the presence of ATP. The purified Drg1
protein was incubated without (red curve) or with (black curve) 740 M diazaborine in the absence (A) or presence (B) of 5 mM ATP. Addition of diazaborine
resulted in a shift of the melting curve to higher temperatures in the presence of ATP, demonstrating binding of the inhibitor to the protein. C and D,
diazaborine binding to Drg1 requires ATP loading into D2. Melting curves of Drg1 variants unable to bind ATP into the first (Drg1KA1 (C)) or the second
(Drg1KA2 (D)) AAA domainwere investigated in the presence of 5mMATPwithout (red curve) or with 740M diazaborine (black curve). Diazaborine treatment
resulted in a change of the melting curve of Drg1KA1 (C) but not Drg1KA2 (D), showing that loading of ATP into D2 is necessary for diazaborine binding. E,
diazaborine binding to Drg1 (WT) in the presence of 5 mM ATP was assessed quantitatively. Melting curves were recorded without diazaborine (red line) or in
the presence of increasing diazaborine concentrations (0–740 M; light gray to black gradient, left panel). Right panel, plotting of the increase in melting
temperature (in relation to theuntreated sample) over thedrug concentration allows the estimationof adrugbinding curve. The calculatedKD ( S.D.) of three
independentmeasurements is shown.F, themeltingcurveof thediazaborine-resistantproteinDrg1-1 (res) showsnoalterationsevenwith740Mdiazaborine,
suggesting that the inhibitor does not bind to this protein.
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calculated a model of Drg1 based on the crystal structure of the
closely related AAA-ATPase p97. p97 shows 45% sequence
identity with Drg1 and is the closest relative for which a crystal
structure is available. As shown in Fig. 4C, all amino acid
exchanges conferring resistance to diazaborine cluster around
the nucleotide binding pocket of the D2 domain, suggesting
that the inhibitor binds in close proximity to the nucleotide.
Diazaborine Specifically Inhibits ATP Hydrolysis in the D2
Domain of Drg1—The data shown above demonstrate that
diazaborine binding to Drg1 requires the presence of nucleo-
tide. Next we tested whether the drug blocks ATP hydrolysis by
Drg1. However, consistent with previous data, the basal
ATPase activity of Drg1 was largely unaffected by the inhibitor
(Ref. 9 and Fig. 5A). Because the ATPase activity of Drg1 is
stimulated by the C-terminal domain of Rlp24 (3) (Rlp24C), we
also tested the effect of diazaborine on the stimulated ATPase
activity. Indeed, in the presence of saturating Rlp24C concen-
trations, the wild-type protein was inhibited by 370 M diaza-
borine by 25%. Higher drug concentrations (i.e. 740 M) did
not further decrease themeasured activity. No inhibition of the
resistant Drg1-1 protein was found evenwith the highest tested
drug concentration (Fig. 5A). Notably, when thewild-typeDrg1
protein was stimulated with lower concentrations of Rlp24C in
the range of theKD (28 nM (3)), we observed amore pronounced
inhibition (60%) in the presence of diazaborine (Fig. 5B). In
contrast, no inhibition of the resistant Drg1-1 variant was
observed throughout all tested Rlp24 concentrations (Fig. 5C).
The fact that ATP hydrolysis was not completely abolished
by the inhibitor suggests that diazaborine only targets one of
the two AAA domains of Drg1 and that in the presence of sat-
urating Rlp24 concentrations the activity of the insensitive
domain is prevailing. Because we have previously shown that
Rlp24 stimulates ATP hydrolysis in both AAAdomains of Drg1
(3), we aimed to identify which of the two domains is targeted
by the drug. For this purpose we purified the Drg1EQ1 and
Drg1EQ2 variants. The fact that these proteins can hydrolyze
ATP only in either the first (EQ2) or the second (EQ1) ATP
binding site allowed us to dissect the influence of the drug on
the individual AAA domains. In the presence of saturating
Rlp24 concentrations, diazaborine inhibited the ATPase activ-
ity of Drg1EQ1 by 80%. Additionally, the basal activity of
Drg1EQ1 was also reduced by the drug by 60  11%, showing
that diazaborine specifically blocks ATP hydrolysis in the sec-
ondAAAdomain (Fig. 5D, inset). In contrast, theATPase activ-
ity of the first AAA domain was not inhibited in the presence of
Rlp24, as the Drg1EQ2 variant was insensitive to the inhibitor.
Notably, the basal ATPase activity observed with this variant,
which is 4-fold higher than that of the wild-type (Fig. 5D and
Ref. 3), was reduced by diazaborine. However, our data clearly
demonstrate that the inhibitor specifically targets the second
AAA domain of Drg1 (Figs. 3 and 4). We therefore suggest that
in Drg1EQ2, the observed inhibition of ATP hydrolysis in D1 in
the absence of Rlp24 is likely an indirect consequence of diaza-
borine binding into D2. Together with the elevated basal activ-
ity of Drg1EQ2 comparedwith thewild-type protein, this result
indicates a pronounced communication from the D2 to the D1
domain.
We have demonstrated previously that the two AAA
domains of Drg1 exhibit different affinities for the nucleotide
(9). To test the influence of ATP loading into D2 on the inhibi-
tion of Drg1, we measured the enzymatic activity of wild-type
Drg1 and the Drg1EQ1 variant in the presence of Rlp24 and
different ATP concentrations (Fig. 5, E and F). At the lowest
tested nucleotide concentration of 0.2 mM ATP, similar ATP
hydrolysis wasmeasuredwith thewild-type protein in the pres-
ence and in the absence of the drug, suggesting that under these
conditions only the diazaborine-insensitiveD1 domain is active
(Fig. 5E). In the presence of higher nucleotide concentrations,
the inhibitor caused a pronounced reduction of ATP hydroly-
sis. In contrast to the wild-type protein, the Drg1EQ1 variant
displayed reduced ATP hydrolysis rates in the presence of
FIGURE4.Mutations leading todiazaborine resistance cluster around the
ATPbindingpocketof theD2domainofDrg1.A, thedrg1-1,drg1-3,drg1-4,
and drg1-11 alleles confer resistance to diazaborine (Dia). Serial dilutions of a
drg1 deletion strain complemented by centromeric plasmids with the indi-
cated drg1 alleles were spotted onto YPDplates or YPDplates containing 370
Mdiazaborine. Plateswere incubated at 30 °C for 3 days. B, schematic shows
Drg1 with the amino acid exchanges causing diazaborine resistance high-
lighted in red. The two AAA-ATPase domains D1 (yellow) and D2 (red) and the
N domain (gray), as well as theWalker A andWalker Bmotifs are indicated. C,
structural model of the region around the nucleotide binding pocket in the
D2 domain of Drg1with bound ADP is shown. Amino acid residues which are
exchanged in the diazaborine-resistant drg1-1, drg1-3, and drg1-11 alleles
are shown in theballmode. The conservedglutamate residue (Glu-617) of the
Walker B motif involved in ATP hydrolysis is depicted in red. The drg1-4 allele
contains a V725L exchange and affects the same residue as the Drg1-1
exchange.
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diazaborine at all tested nucleotide concentrations, even at 0.2
mM (Fig. 5F; compare first data points in Fig. 5, E and F). Taken
together, these results suggest that the D2 domain represents
the low affinity ATP binding site which is specifically targeted
by diazaborine.
Blockage of ATP Hydrolysis in D2 Correlates with Growth
Inhibition—To evaluate how the inhibition of ATP hydrolysis
in D2 by diazaborine affects growth, we measured the ATPase
activity as well as the growth of yeast cells in the presence of
increasing drug concentrations. We focused on the Drg1EQ1
variant as in the wild-type protein, both AAA domains are acti-
vated under saturating Rlp24C concentrations, but only D2 is
inhibited by diazaborine (Fig. 5D). As shown in Fig. 6A, in the
presence of saturating Rlp24C concentrations, the ATPase
activity of both, the Drg1 wild-type and the EQ1 variant was
inhibited by increasing diazaborine concentrations. The Ki of
diazaborine for the D2 domain was estimated to approximately
26 M. A significant decrease in cell density of both the wild-
type and the drg1EQ1 mutant was observed at a drug concen-
tration corresponding to the Ki of diazaborine for the D2
domain (Fig. 6B). These results demonstrate a clear correlation
between the inhibition of ATP hydrolysis in D2 and the
decrease in proliferation of yeast cells in vivo.
DISCUSSION
Ribosome biogenesis in eukaryotic cells involves the coordi-
nated activity of 200 trans-acting factors. Because most of
FIGURE 5. Diazaborine (Dia) only inhibits ATP hydrolysis in the D2 domain of Drg1. A, the ATPase activity of Drg1 is inhibited by diazaborine. ATPase
activity of 1200 nM (corresponding to 200 nM hexamer) purified wild-type Drg1 (WT) or the Drg1-1 (res) protein was measured in the absence or presence of
Rlp24C (800 nM) and diazaborine (370M). In addition, the inhibition of the stimulated ATPase activity was also tested in the presence of 740M diazaborine.
Error bars, S.D. of three biological replicates. B and C, Drg1 wild-type protein (B) or the diazaborine-resistant variant Drg1-1 (C) were incubated in the presence
of different Rlp24C concentrations (0–800 nM) and 370M diazaborine. Error bars, S.E. of three biological replicates.D, only the second AAA domain of Drg1 is
inhibited by diazaborine. Effect of diazaborine (370M) on the ATPase activity of mutant variants of Drg1 defective for ATP hydrolysis in the first (Drg1EQ1) or
second (Drg1EQ2)AAAdomain is shown.ATPaseactivitywasmeasured in theabsenceorpresenceof 800nMRlp24C. Inset, enlargeddisplayof thebasal activity
of theDrg1wild-type (WT) protein and theDrg1EQ1 variant (EQ1) in the presence and absence of diazaborine. Error bars, S.D. of twobiological replicates. E and
F, ATP dependence of the inhibition of Drg1 and Drg1EQ1 by diazaborine. The ATPase activity of Drg1 in the presence of 20 nM and 800 nM Rlp24C (E) and of
the Drg1EQ1 variant in the presence of 800 nM Rlp24 (F) was tested using increasing ATP concentrations without and with 370 M diazaborine. The ATPase
activity in the absence of Rlp24 (basal activity) is shown as a gray line. Error bars, S.E. of two biological replicates.
FIGURE 6.BlockageofATPhydrolysis inD2parallels growth inhibition.A,
the ATPase activity of Drg1EQ1 was measured in the presence of 800 nM
Rlp24C using increasing concentrations of diazaborine (Dia). The relative
activity values were plotted against the logarithmic inhibitor concentration.
The Ki determined with Drg1EQ1 is indicated by a dashed line. The activity of
wild-typeDrg1 (WT) is shownas a control. B, growth inhibition of the drg1EQ1
mutant is shown upon diazaborine treatment. Cells were grown in the pres-
ence of increasing diazaborine concentrations for 24 h, the A600 was mea-
sured, and the relativeA600 valueswere plotted against the logarithmic inhib-
itor concentration. The inhibitor concentration corresponding to the Ki
determined in A is indicated by a dashed line.
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these factors are essential, ribosome biogenesis provides a
promising target for antimicrobial and anti-tumor chemother-
apy. In this study, we investigated the mechanism of action of
the first specific inhibitor of this pathway, the heterocyclic
boron-containing compound diazaborine. Our data demon-
strate that the AAA-ATPase Drg1 is the direct target of diaza-
borine. Drg1 is only found in eukaryotic cells and was previ-
ously shown to be a key factor of pre-60S ribosome maturation
in yeast. Accordingly, treatmentwith the drug leads to the same
phenotypic consequences as those caused by the functional
inactivation of Drg1, i.e. a failure to release Rlp24 from pre-60S
particles and a block in downstream maturation (Fig. 1, com-
pare with Ref. 3).
What is the mechanism of inhibition of the drug? Our work
shows that diazaborine specifically binds into the second AAA
domain ofDrg1 and thereby inhibits ATPhydrolysis in this site.
However, the drug does not act as a competitive inhibitor for
ATP. Instead, ATP binding to D2 is a prerequisite for diazabo-
rine to recognize Drg1. Nucleotide binding is also required for
inhibitor interaction with the enoyl-ACP reductase (FabI),
which is the target of diazaborine in Gram-negative bacteria.
For FabI, it was shown that the NAD cofactor has to bind to
the enzyme to enable interaction with the inhibitor (12, 13).
Structural studies showed that in the active site of FabI, the
boron atom of diazaborine forms a covalent bond with the
2-OHof the nicotinamide ribosemoiety of theNAD cofactor
(26, 27). It is however currently unknown whether or not bind-
ing of diazaborine toDrg1 also involves the formation of a cova-
lent bond between ATP and the inhibitor. Our homology
model of Drg1 shows that all up to now identified amino acid
exchanges causing resistance to diazaborine are located in close
proximity to the nucleotide in the D2 domain of the protein
(Fig. 4C). This observation supports the possibility of a close
contact betweenATP and diazaborine within theD2 domain of
Drg1. Therefore, formation of covalent intermediates or at least
tight binding between a nucleotide cofactor and the inhibitor
could be a general principle for the mode of action of diazabo-
rine. Our structural model also offers an explanation for the
resistance mechanism: Themutations resulting in the resistant
phenotype in the drg1-1, drg1-3, and drg1-4 alleles introduce
amino acid residues with bulkier side chains than those present
in the wild-type and therefore may reduce the accessibility of
the binding pocket for the drug. As diazaborine is unable to
bind to the Drg1-1 protein, the resistance mechanism may
involve the occlusion of diazaborine from its binding site near
the D2 nucleotide binding pocket of Drg1.
Taken together, our work shows that ribosome biogenesis in
general and particularly energy-consuming enzymes within
this pathway may represent promising targets for the develop-
ment of novel inhibitors. These enzymes include additional
AAA-ATPases, like Rix7 and Rea1, but also a number of RNA
helicases and GTPases (1). Furthermore, AAA-ATPases have
emerged as interesting new targets for low molecular weight
inhibitors in recent years. For example, significant efforts were
undertaken to identify inhibitors for p97/VCP (28–31), which
is closely related to Drg1 but involved in different cellular path-
ways. The mechanistic insights gained from our study will
therefore be helpful for the rational design of novel inhibitors of
other AAA-ATPases.
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